Orion Biopharmaceuticals is developing a new, therapeutic approach for the treatment of auto-immune diseases through specific interaction with the immune cells responsible for disease progression.
Products / Services
Orion Biopharmaceuticals has developed a therapeutic technology for the treatment of autoimmune diseases, specifically Relapse-Remitting Multiple Sclerosis, through the use of a peptide-polymer conjugate identified as Soluble Antigen Array (SAgA).
Leonard, A.K., Sestak, J.O., Costantino, H.R., Sileno, A.P., Peddakota, L.R., Sharghi, K.E., Bellamy, G.M., Gesty, J.P., (2009), “INTRANASAL CARBETOCIN FORMULATIONS AND METHODS FOR THE TREATMENT OF AUTISM,” U.S. Patent Application 20100311655.
Quay, S.C., …, Sestak, J.O., (2008), “Pharmaceutical Formation For
Increased Epithelial Permeability of Glucose-Regulating Peptide,” U.S. Patent Application 20080318837
Quay, S.C, …., Sestak, J.O., (2007), “COMPOSITIONS AND METHODS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS,” U.S. Patent Application 20070032410.
1st Prize Research Poster Presentation at the Global Pharmaceutical Education Network (GPEN) Conference November 2010
2011 Recipient of The University of Kansas Graduate Research Presentation Award
Amgen Graduate Travelship for 2011 American Association of Pharmaceutical Scientists National Biotechnology Conference
1st Place Institute for Advancing Medical Innovation Venture Pitch Competition, July 2011